View Older Stories
-
Natera submits bladder cancer diagnostic test to FDA for approval
-
Natera completes enrollment in heart transplant trial testing blood-based monitoring
-
Natera publishes validation study for colorectal cancer test
-
Natera's prenatal test selected for plenary presentation at medical meeting
-
Natera develops AI model to enhance cancer risk assessment
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Natera reports preliminary 2025 revenue growth of 35% to $2.3 billion
-
Citi Starts Natera (NTRA) at Buy
-
Natera reports significant survival benefit in ALTAIR colorectal cancer trial
-
Natera publishes colorectal cancer study results in JAMA Oncology
-
Natera's Signatera test improves breast cancer recurrence prediction
-
Natera (NTRA) PT Raised to $275 at Jefferies
-
TD Cowen on Natera (NTRA): 'Management Meetings Reflect Solid Momentum With Levers for Upside'
-
Natera's MRD test shows prognostic value in breast cancer study
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Natera (NTRA) files for 1.95M share offering by selling stockholders
-
Natera acquires Foresight Diagnostics for up to $450 million
-
Morgan Stanley Assumes Natera (NTRA) at Overweight
-
Natera (NTRA) PT Raised to $235 at Stephens
-
Natera (NTRA) PT Raised to $240 at TD Cowen
-
Natera (NTRA) PT Raised to $250 at Evercore ISI
-
Natera (NTRA) PT Raised to $230 at BTIG
-
Natera (NTRA) Misses Q3 EPS by 27c; offers guidance
-
Piper Sandler Reiterates Overweight Rating on Natera (NTRA)
-
Natera reports blood test shows 22.5% sensitivity for precancerous polyps
-
BNP Paribas Exane Upgrades Natera (NTRA) to Neutral
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Natera (NTRA) PT Raised to $210 at BTIG
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Natera enrollment exceeds 1,600 patients in single gene NIPT trial
-
Natera publishes testicular cancer study showing Signatera outperforms tumor markers
-
NATERA study shows Signatera detected all uterine cancer recurrences
-
Wells Fargo Resumes Natera (NTRA) at Equal Weight
-
Piper Sandler on Natera (NTRA): 'IMvigor011 Changes the Game in More Ways than Expected'
-
Natera loses patent ruling in NeoGenomics litigation
-
Natera's Signatera test selected for bladder cancer trial
-
Natera launches AI foundation models for oncology drug development
-
UBS Reiterates Buy Rating on Natera (NTRA)
-
Natera's Signatera test shows positive results in bladder cancer trial
-
Natera (NTRA) PT Raised to $255 at RBC Capital
-
Natera (NTRA) PT Raised to $205 at Bernstein SocGen Group
-
Natera (NTRA) PT Raised to $215 at TD Cowen
-
Natera (NTRA) Misses Q2 EPS by 12c; offers guidance
-
Natera launches noninvasive prenatal test for inherited conditions
-
Evercore ISI Starts Natera (NTRA) at Outperform
-
BTIG names top large-cap picks for second half of 2025
-
Supreme Court Braidwood ruling is positive for DX names like DHR, EXAS, NTRA, HOLX, QDEL - RBC Capital
-
Leerink Partners Reiterates Outperform Rating on Natera (NTRA)
-
Natera (NTRA) Announces Medicare Coverage for Signatera Genome
-
RBC Capital on Natera (NTRA): 'Beats Never Looked So Good'

